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Abstract
Background: The transcription factor Runx2 has an established role in cancers that metastasize to bone. In metastatic 
breast cancer cells Runx2 is overexpressed and contributes to the invasive capacity of the cells by regulating the 
expression of several invasion genes. CBFβ is a transcriptional co-activator that is recruited to promoters by Runx 
transcription factors and there is considerable evidence that CBFβ is essential for the function of Runx factors. However, 
overexpression of Runx1 can partially rescue the lethal phenotype in CBFβ-deficient mice, indicating that increased 
levels of Runx factors can, in some situations, overcome the requirement for CBFβ. Since Runx2 is overexpressed in 
metastatic breast cancer cells, and there are no reports of CBFβ expression in breast cells, we sought to determine 
whether Runx2 function in these cells was dependent on CBFβ. Such an interaction might represent a viable target for 
therapeutic intervention to inhibit bone metastasis.
Results: We show that CBFβ is expressed in the metastatic breast cancer cells, MDA-MB-231, and that it associates with 
Runx2. Matrigel invasion assays and RNA interference were used to demonstrate that CBFβ contributes to the invasive 
capacity of these cells. Subsequent analysis of Runx2 target genes in MDA-MB-231 cells revealed that CBFβ is essential 
for the expression of Osteopontin, Matrixmetalloproteinase-13, Matrixmetalloproteinase-9, and Osteocalcin but not for 
Galectin-3. Chromatin immunoprecipitation analysis showed that CBFβ is recruited to both the Osteopontin and the 
Galectin-3 promoters.
Conclusions: CBFβ is expressed in metastatic breast cancer cells and is essential for cell invasion. CBFβ is required for 
expression of several Runx2-target genes known to be involved in cell invasion. However, whilst CBFβ is essential for 
invasion, not all Runx2-target genes require CBFβ. We conclude that CBFβ is required for a subset of Runx2-target 
genes that are sufficient to maintain the invasive phenotype of the cells. These findings suggest that the interaction 
between Runx2 and CBFβ might represent a viable target for therapeutic intervention to inhibit bone metastasis.
Background
CBFβ is a transcriptional co-activator that is recruited to
promoters by members of the Runx family of transcrip-
tion factors. Runx transcription factors are defined by the
presence of a conserved DNA-binding domain, termed
the Runt domain, that recognises the consensus sequence
ACC(A/G)CA [1]. The Runt domain also interacts with
CBFβ. CBFβ binds to the non-DNA-binding surface of
the Runt domain to induce structural changes in the
DNA-recognition surface, thereby increasing its affinity
for DNA [2,3]. CBFβ is essential for haematopoiesis and
the development of the skeleton, by virtue of its interac-
tion with Runx proteins [4-6]. Indeed, CBFβ is essential
for most of the known functions of Runx proteins. How-
ever, there is evidence that in some situations Runx pro-
teins can regulate gene expression independently of
CBFβ. In the sea urchin, CBFβ is not required for expres-
sion of the Runx target gene PKC1 [7,8]. Moreover, over-
expression of Runx1 partially rescued the lethal
phenotype in CBFβ-deficient mice, indicating that over-
expressed Runx1 can regulate gene expression in the
absence of CBFβ [9].
Runx2 is overexpressed in breast cancer cell lines that
metastasize to bone where it has an established role in
invasion. When Runx2 function was inhibited in meta-
static breast cancer cells transplanted to bone, tumori-
genesis and osteolysis were prevented [10]. Runx2
regulates the expression of several genes known to be
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involved in cell migration and metastasis including,
Matrixmetalloproteinase-13 (MMP-13) and Matrixmet-
alloproteinase-9 (MMP-9), Vascular Endothelial Growth
Factor (VEGF) and Bone Sialoprotein (BSP)[11-13]. Abla-
tion of Runx2 expression in metastatic breast cancer cells,
MDA-MB-231, resulted in down-regulation of metastatic
genes and reduced the invasive capacity of the cells [12].
However, it is not known if the increased expression of
Runx2 observed in metastatic breast cancer cells is suffi-
cient to regulate gene expression independently of CBFβ.
Indeed, it is not known if CBFβ is expressed in metastatic
breast cancer cells.
Here we demonstrate that CBFβ is expressed in meta-
static breast cancer cells and that it is essential for cell
invasion. We also show that several Runx2-target genes,
known to be involved in cell invasion, require CBFβ.
However, whilst CBFβ is essential for invasion not all
Runx2 target genes require CBFβ. We conclude that
CBFβ is required for a subset of Runx2-target genes that
are sufficient to maintain the invasive phenotype of the
cells. These findings suggest that the interaction between
Runx2 and CBFβ might represent a viable target for ther-
apeutic intervention to inhibit bone metastasis.
Results
CBFβ is associated with Runx2 in the metastatic breast 
cancer cell line MDA-MB-231
Previous reports have shown that compared to non-met-
astatic cells Runx2 is overexpressed in the metastatic
breast cancer cells, MDA-MB-231 [13,14]. Overexpres-
s i o n  o f  R u n x 1  i s  k n o w n  t o  be  s u f f i c i e n t  t o  r e s c u e  t h e
lethal phenotype in CBFβ-deficient mice, indicating that
increased levels of Runx factors can at least partially over-
come the requirement for CBFβ [9]. To determine
whether CBFβ has a role in the invasive capacity of meta-
static MDA-MB-231 cells we first established that it is
expressed in these cells. Immunoblotting of total cell
extracts with an anti-CBFβ antibody demonstrated that
CBFβ is present in both MDA-MB-231 and the non-met-
astatic MCF-7 cells (Fig. 1A). CBFβ was also observed in
the osteosarcoma cell line, UMR-106, and HeLa cells (Fig.
1A). CBFβ is therefore expressed in both metastatic and
non-metastatic breast cancer cell lines. However, in
nuclear extracts, CBFβ was present in MDA-MB-231 and
UMR-106 cells but not in MCF-7 and HeLa cells (Fig. 1B).
In agreement with previous reports, western blotting
demonstrated that Runx2 is expressed in the metastatic
MDA-MB-231 cells but was not detectable in non-meta-
static MCF-7 cells (Figs. 1B &1C). Runx2 is expressed in
UMR-106 cells but not in HeLa cells, which were used as
positive and negative controls respectively. Thus, CBFβ is
present in the nucleus of cells expressing Runx2.
To establish if CBFβ is associated with Runx2 in MDA-
MB-231 cells, endogenous Runx2 was immunoprecipi-
tated with an anti-Runx2 antibody followed by western
blotting with an anti-CBFβ antibody (Fig. 1D). CBFβ co-
precipitated with Runx2 in both MDA-MB-231 and
UMR-106 (Fig. 1D, lanes 3 & 6). The association was spe-
cific, as CBFβ did not co-precipitate with a non-specific
IgG antibody (Fig. 1D, lanes 2 & 5). These data demon-
strate that the Runx2/CBFβ complex is present in MDA-
MB-231 cells.
Depletion of CBFβ in MDA-MB-231 cells reduces their 
invasive capacity
Having shown that MDA-MB-231 cells express CBFβ we
next sought to determine whether CBFβ contributed to
their invasive capacity. siRNAs were therefore used to
knock down CBFβ by transient transfection of MD-MB-
231 cells. Matrigel invasion assays were subsequently per-
formed to determine the migratory capacity of the cells.
CBFβ protein was reduced by over 90% in cells trans-
fected with siRNAs targeted against CBFβ, but was unaf-
fected in non-specific siRNA control transfections (Fig.
2A). Cells with reduced CBFβ expression exhibited signif-
icantly less invasion (34%) than control cells (90%) when
compared with wild-type MDA-MB-231 cells (100%)
(Fig. 2B). Decreased expression of CBFβ therefore signifi-
cantly reduces the invasive capacity of MDA-MB-231
cells. These findings mirrored the effect of knocking
down Runx2 which, in agreement with a previous report,
also significantly inhibited the invasion capacity of MDA-
MB-231 cells (Figs. 2C &2D)[12].
To confirm our findings using siRNAs we also estab-
lished a stable cell line derived from MDA-MB-231 cells
in which CBFβ expression was reduced using plasmids
encoding short-hairpin RNAs (shRNAs). MDA-MB-231
cells were stably transfected with shRNA plasmids tar-
geted against human CBFβ. Two independent cell lines
were derived in which expression of endogenous CBFβ
protein was reduced by over 80%, as determined by
immunoblotting (Fig. 3A; shCBFβ, shCBFβ2). In contrast,
CBFβ expression was unaffected in an independent cell
line harbouring a non-specific shRNA plasmid (Fig. 3A,
shNS). Runx2 protein levels were also unaffected by
knockdown of CBFβ, indicating that CBFβ is not required
to maintain the stability of Runx2 (Fig. 3B). Matrigel inva-
sion assays were subsequently performed using the CBFβ
knockdown cell lines. Cells with reduced CBFβ expres-
sion exhibited significantly less invasion (19%) than con-
trol cells (75%) when compared with wild-type MDA-
MB-231 cells (100%) (Fig. 3C). Thus, we have demon-
strated, using two independent RNA interference meth-
ods that CBFβ contributes to the invasive capacity of
metastatic breast cancer cells.
CBFβ is essential for expression of invasion genes in MDA-
MB-231 cells
We next investigated the role of CBFβ in regulating the
expression of a selection of Runx2-target genes. mRNAMendoza-Villanueva et al. Molecular Cancer 2010, 9:171
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levels were measured by real-time RT-PCR in cells trans-
fected with siRNAs targeted against CBFβ. The expres-
sion of two genes, Matrixmetalloproteinase-13 (MMP-
13) and Matrixmetalloproteinase-9 (MMP-9), that are
known to be involved in invasion and have been shown to
be regulated by Runx2 in metastatic breast cancer cells,
was examined [12,15]. We also examined the expression
of two other Runx2-target genes, OPN and Galectin-3,
whose expression is strongly associated with metastasis
but neither has been shown to be regulated by Runx2 in
metastatic breast cancer cells [16-21]. In addition, Osteo-
calcin (OC) expression was monitored, as this gene is
known to be dependent on both Runx2 and CBFβ in
osteoblasts [22]. Endogenous levels of OPN, MMP-13,
MMP-9, OC and Galectin-3 mRNA were measured by
real-time RT-PCR (Fig. 4A). The depletion of CBFβ
resulted in a significant decrease in the expression of
OPN, MMP-13, MMP-9 and OC, four of the Runx2-tar-
get genes, but no significant change in Galectin-3 expres-
sion was observed (Fig. 4A). A very similar expression
profile was observed in stably transfected CBFβ-knock-
down cells (Fig. 4B). We note that whilst the magnitude of
some of the differences in gene expression is not as great
in the stable knock-down cells, compared to the transient
siRNA knockdowns, the direction of the changes and the
overall trend is identical in both cases. These findings
Figure 1 CBFβ is associated with Runx2 in the metastatic breast cancer cell line MDA-MB-231. (A) Western blot showing CBFβ expression in 
MDA-MB-231 cells. Total extracts from metastatic (MDA-MB-231) and non-metastatic (MCF-7) breast cancer cell lines were subjected to western blot-
ting analysis with a CBFβ antibody. HeLa cells known to express CBFβ were used as positive controls. Protein levels of Tubulin are shown as an internal 
loading control. (B) CBFβ and Runx2 are nuclear in MD-MB-231 cells. Nuclear extracts from MDA-MB-231 and MCF-7 cells were utilized to determine 
the localisation of Runx2 and CBFβ. Lamin B1 was used as loading control. (C) Western blot showing Runx2 expression in MDA-MB-231 cells. Total 
extracts from metastatic (MDA-MB-231) and non-metastatic (MCF-7) breast cancer cell lines were subjected to western blotting analysis with a Runx2 
antibody. The UMR-106 and HeLa cells were used as positive and negative controls for Runx2 expression, respectively. Protein levels of Tubulin are 
shown as an internal loading control. (D) Runx2 interacts with CBFβ in MDA-MB-231 cells. Whole extracts of the UMR-106 and MDA-MB-231 cells were 
subject to immunoprecipitation (IP) assays. A monoclonal antibody against Runx2 was used to immunoprecipitate the Runx2 protein. Then, immu-
noblots with a polyclonal antibody anti-CBFβ (upper) or a whole serum anti-Runx2 (lower) were used to determine the presence of CBFb and Runx2, 
respectively. IgG antibody was used as a specificity control. Whole extracts of the cells (input) were used as control for CBFβ and Runx2 expression.
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indicated that Runx2 and CBFβ are both required for
expression of OPN, MMP-13, MMP-9 and OC but that
Galectin-3 expression was independent of CBFβ. To
establish if all five genes are indeed regulated by Runx2 in
MDA-MB-231 cells, Runx2 expression was knocked
down, using siRNAs. Depletion of Runx2 resulted in a
significant decrease in the expression of all five genes
(Fig. 4C). These data demonstrate that CBFβ is essential
for full expression of OPN, MMP-13, MMP-9 and OC but
not for Galectin-3. However, all five genes are dependent
on Runx2, thus confirming that MMP-13, MMP-9 and
OC are Runx2 targets in MDA-MB-231 cells and addi-
tionally demonstrating that OPN and Galectin-3 are
Runx2 targets in these cells.
We subsequently used chromatin immunoprecipitation
(ChIP) to determine whether CBFβ was selective for indi-
vidual promoters by comparing the presence of CBFβ on
the OPN and Galectin-3 promoters. Real-time PCR was
used to amplify the OPN and Galectin-3 promoters after
immmunoprecipitation of fragmented chromatin with
either CBFβ-specific or Runx2-specific antibodies. Com-
pared to non-specific IgG controls the OPN and Galec-
tin-3 promoters were enriched approximately 3.5-fold
with the CBFβ-specific antibody and 5-fold with the
Figure 2 siRNA-mediated depletion of CBFβ in MDA-MB-231 cells inhibits their invasive capacity. (A) Western blot showing siRNA knockdown 
of CBFβ. The upper panel shows total cell lysates derived from siRNA transfections of MDA-MB-231 cells after immunodetection with an anti-CBFβ 
antibody. The lower panel is a Tubulin loading control. (B) MDA-MB-231 cells were transfected with siRNA against CBFβ (siCBFβ) and a non-specific 
siRNA (siNS). 24 hrs after a second transfection the cells were plated on Matrigel for invasion assays. Wild type (WT) MDA-MB-231 cells were used as 
positive control for invasion. Cells that migrated were stained and counted in random fields. Data are presented as mean ± standard deviation (S.D.) 
(n = 3). * indicates p < 0.05 compared with siNS by analysis of variance. (C) Western blot showing siRNA knockdown of Runx2. The upper panel shows 
total cell lysates derived from siRNA transfections of MDA-MB-231 cells after immunodetection with an anti-Runx2 antibody. The lower panel is a Tu-
bulin loading control. (D) Runx2 is required for invasion of MDA-MB-231 cells. MDA-MB-231 cells were transfected with siRNA against Runx2 (siRunx2) 
or a non-specific siRNA (siNS). 24 hrs after a second transfection the cells were plated on Matrigel for invasion assays. Wild type (WT) MDA-MB-231 cells 
were used as a positive control for invasion. Cells that migrated were stained and counted in random fields. Data are presented as mean ± standard 
deviation (S.D.) (n = 3). * indicates p < 0.05 compared with siNS by analysis of variance.
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Runx2-specific antibody (Figs. 4D &4E). Taken together,
these findings demonstrate that CBFβ is recruited to both
OPN and Galectin-3 promoters but is not essential for
Galectin-3 activation.
Re-expression of CBFβ restores invasion capacity and OPN 
expression
We next tested the ability of CBFβ to restore the invasive
capacity of MDA-MB-231 cells in which CBFβ had previ-
ously been knocked down. To prevent the re-introduced
CBFβ from being knocked down by siRNAs targeted
against the endogenous protein, mouse CBFβ was used.
To distinguish the mouse CBFβ from the endogenous
human protein in immunoblots it was also tagged with
Flag and HA sequences; we refer to this protein as CBFβ*.
Endogenous CBFβ was knocked down in MDA-MB-231
cells, followed by transfection with a plasmid encoding
CBFβ* (Fig. 5). Cells transfected with CBFβ siRNAs and
the CBFβ* plasmid expressed CBFβ* but not the endoge-
nous CBFβ, as determined by immunoblotting (Fig. 5A).
Neither form of CBFβ was observed in control transfec-
tions with siRNAs and pcDNA3, whereas endogenous
CBFβ was expressed in transfections with non-specific
siRNAs and pcDNA3 (Fig. 5A). Matrigel invasion assays
subsequently demonstrated that the expression of CBFβ*
restored the invasive capacity of the cells to similar levels
observed with the non-specific siRNA controls (Fig. 5B).
To examine the effect of CBFβ* on gene expression we
measured OPN and MMP-13 mRNA levels. When CBFβ*
was expressed in cells transfected with CBFβ siRNAs,
OPN mRNA levels were restored to similar levels
observed in the non-specific siRNA transfectants (Fig.
5C). We also examined the effect of CBFβ* on the activity
of the OPN promoter in CBFβ-depleted MDA-MB-231
cells (Fig. 5D). MDA-MB-231 cells transfected with
siCBFβ or siNS were transfected with a plasmid contain-
ing the WT human OPN promoter or a mutant OPN pro-
moter in which the Runx2-binding sites were mutated.
The relative reporter activity was obtained by compari-
son of the WT promoter activity with the mutant pro-
moter activity. In the absence of CBFβ the activity of the
OPN promoter decreased by 35% compared to the non-
specific siRNA controls and was restored to similar levels
as the controls when CBFβ* was expressed (Fig. 5D).
CBFβ* also restored MMP-13 mRNA expression and
stimulated activity of the MMP-13 promoter (Figs. 5E
&5F). Taken together, these data show that CBFβ is a pos-
itive regulator of metastatic-gene expression and cell
invasion.
Discussion
In this study we established that CBFβ is expressed in
MDA-MB-231 cells and that it is essential for cell inva-
sion. We subsequently demonstrated that CBFβ partici-
Figure 3 Stable knockdown of CBFβ inhibits invasion of MDA-
MB-231 cells. (A) Western blot showing knockdown of CBFβ in two in-
dependent clones. Total lysates from wild type (WT) MDA-MB-231 cells 
and two stable transfectants harbouring a plasmid containing shRNAs 
against CBFβ (shCBFβ) or a plasmid with a non-specific shRNA (shNS) 
were subject to western blotting analysis to determine CBFβ expres-
sion. Tubulin was used as a loading control. (B) Western blot showing 
expression of Runx2 in CBFβ-knockdown cells. The upper panel shows 
nuclear extracts from stable knockdown cells (shCBFβ) and the stable 
non-specific cells (shNS) after immunodetection with an anti-Runx2 
antibody. The lower panel is a Lamin B1 loading control. (C) CBFβ is es-
sential for invasion. Both CBFβ-knockdown clones and the non-specific 
stable clone were plated on Matrigel to determine their invasive ca-
pacity. Wild type (WT) MDA-MB-231 cells were used as positive control 
for invasion. Cells that migrated were stained and counted in random 
fields. Data are presented as mean ± standard deviation (S.D.) (n = 3). * 
indicates p < 0.05 compared with shNS by analysis of variance.
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Figure 4 CBFβ and Runx2 are required for expression of metastatic genes in MDA-MB-231 cells. (A) CBFβ regulates Runx2-dependent meta-
static genes in MDA-MB-231 cells. MDA-MB-231 cells transfected with siCBFβ or a non-specific siRNA were subject to real-time RT-PCR. Total RNAs 
were used to analyze the mRNA levels of known Runx2 target genes as indicated. Acidic ribosomal phosphoprotein P0 (RPLO) mRNA was used as a 
control for normalization and relative values are shown. Data are presented as mean ± standard deviation (S.D.) (n = 3). Statistical evaluation of signif-
icant differences was performed using the Student's t-test. Asterisk (*) indicates P < 0.05 when compared to control (siNS). (B) Stable knockdown cells 
(shCBFβ) and the non-specific cells (shNS) were subject to real-time RT-PCR. Data were analyzed as in (A) except that * indicates P < 0.05 when com-
pared to control (shNS). (C) Runx2 regulates metastatic genes in MDA-MB-231 cells. MDA-MB-231 cells transfected with siRunx2 and a non-specific 
siRNA were subject to real-time RT-PCR. Data were analyzed as in (A). (D) CBFβ is recruited to the OPN promoter in MDA-MB-231 cells. ChIP assays 
using Runx2 and CBFβ antibodies. The relative enrichment of the OPN sequence was determined by comparing the DNA from specific antibody to 
that from control IgG then normalized with non-specific genomic DNA. Data are presented as mean ± standard deviation (S.D.) (n = 3). * indicates p 
< 0.05 compared with IgG by analysis of variance. (E) CBFβ is recruited to the Galectin-3 promoter. ChIP assays using Runx2 and CBFβ antibodies. Data 
were analyzed as in (D).
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Figure 5 Re-expression of CBFβ restores invasion capacity and OPN and MMP-13 expression. (A) Western blots showing re-expression of CBFβ 
after siRNA knockdown. The upper panel shows total cell lysates after immunodetection with an anti-CBFβ antibody. (B) Re-expression of CBFβ re-
stores invasive capacity. MDA-MB-231 cells were transfected with siCBFβ or siNS. siCBFβ treated cells were transfected with the Flag-CBFβ-HA expres-
sion plasmid (CBFβ*). Cells that migrated through Matrigel were stained and counted in random fields. Data are presented as mean ± standard 
deviation (S.D.) (n = 3). * indicates p < 0.05 compared to siNS by analysis of variance; # indicates p < 0.05 compared to siCBFβ by analysis of variance. 
(C) Re-expression of CBFβ restores OPN gene expression. MDA-MB-231 cells transfected with siCBFβ or siNS followed by transfection with the CBFβ* 
expression plasmid. Data were analyzed as in (B). (D) Re-expression of CBFβ stimulates the OPN gene promoter. MDA-MB-231 cells transfected with 
siCBFβ or siNS were transfected with a plasmid containing the WT OPN promoter or a mutant OPN promoter containing mutated Runx2 sites. Cells 
were subsequently transfected with the CBFβ* expression plasmid. Reporter activity was obtained by comparison of the WT and mutant promoter 
activities. Data were analyzed as in (B). (E) MMP-13 gene expression is restored by re-expression of CBFβ. The experiment was performed as described 
in (C). (F) Re-expression of CBFβ stimulates the MMP-13 gene promoter. The experiment was performed as described in (D) using reporter plasmids 
containing the WT human MMP-13 promoter or a mutant MMP-13 promoter containing mutated Runx2 sites.
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pates in the activation of genes implicated in cell invasion.
Importantly, re-expression of CBFβ in the CBFβ-knock-
down cells restored the invasive capacity. The restored
invasive capacity was also accompanied by an increase in
CBFβ-target gene expression, as exemplified by the
increased expression of OPN. We also demonstrated that
the metastatic genes OPN and Galectin-3 are Runx2-tar-
gets in metastatic breast cancer cells. However, whilst
CBFβ was essential for the expression of OPN, MMP-13,
MMP-9 and OC it was not required for Galectin-3
expression, despite the fact that CBFβ is recruited to the
Galectin-3 promoter. CBFβ is therefore functionally
redundant with respect to Galectin-3 expression in
MDA-MB-231 cells. Together, our data demonstrate that
CBFβ is essential for invasion of metastatic breast cancer
cells and that the expression level of Runx2 is not suffi-
cient to overcome the requirement for CBFβ, at least at a
subset of Runx2-target genes.
The finding that CBFβ was present on the promoter of
Galectin-3 was surprising, given that CBFβ is not
required for Galectin-3 expression. One explanation for
this might be that whilst CBFβ can be recruited to the
Galectin-3 promoter it is not essential for Runx2 binding,
possibly due to the presence of other cooperating tran-
scription factors. Precedence for such a scenario has been
demonstrated for Runx1, whereby the DNA-binding
activity of Runx1 is enhanced by the cooperating tran-
scription factor Ets-1 [23,24].
Our finding, that not all Runx2-target genes require
CBFβ for their expression, is consistent with the observa-
tion that in CBFβ-deficient mice overexpression of Runx1
can only partially overcome the requirement for CBFβ.
However, in MDA-MB-231 cells the genes that are
dependent on CBFβ must be required for invasion since
this process is inhibited in the absence of CBFβ. Presum-
ably in the Runx1 mouse model the high expression of
Runx1 is sufficient to activate a subset of genes in some
cells that enables the partial rescue. The primary function
of CBFβ is to enhance DNA-binding of Runx proteins and
so in the absence of CBFβ, binding of Runx proteins to
their target genes will be compromised. We envisage that
in some cases overexpression of Runx proteins is suffi-
cient to raise the intracellular concentration to a level that
enables them to bind to a subset of target genes indepen-
dently of CBFβ. Indeed, in addition to the experimental
overexpression of Runx1 there are examples in nature
where Runx proteins appear to function in the absence of
CBFβ. In the sea urchin, CBFβ is not required for expres-
sion of the Runx-target gene PKC1, nor is it recruited to
the promoter [7,8]. In the chicken, Runx1 is highly
expressed in the dorsal pharyngeal region but CBFβ is not
[25], and in C. elegans CBFβ is restricted to the hypoder-
mis whereas the Runx protein, RNT-1, is expressed in the
intestine [26]. However, it is not clear at present whether
a high intracellular concentration of Runx proteins in
these situations is the determining factor that enables
them to bind to their target genes in the absence of CBFβ.
Perturbation of Runx2 regulatory function by mutagen-
esis in MDA-MB-231 cells has been shown to abolish
their capacity to form osteolytic lesions in the bone, sug-
gesting that modulating Runx2 function might be a viable
means of inhibiting bone metastases [10]. Thus, our find-
ing that CBFβ is required for Runx2 to regulate meta-
static genes indicates that disruption of this interaction
would also inhibit the formation of metastases. Indeed,
previous work has shown that proliferation of the human
leukemia cell line ME-1 can be inhibited by compounds
that disrupt the interaction between Runx1 and CBFβ
[27]. Such compounds may also be able to disrupt the
Runx2/CBFβ interaction in metastatic breast cancer cells.
The Runx2/CBFβ interaction might therefore represent a
viable therapeutic target in metastatic breast cancer.
Conclusions
CBFβ is expressed in metastatic breast cancer cells and is
essential for cell invasion. CBFβ is required for expression
of several Runx2-target genes known to be involved in
cell invasion. However, whilst CBFβ is essential for inva-
sion, not all Runx2-target genes require CBFβ. We con-
clude that CBFβ is required for a subset of Runx2-target
genes that are sufficient to maintain the invasive pheno-
type of the cells.
Methods
Cell lines and cell culture
The non-metastatic MCF-7 and metastatic MDA-MB-
231 human breast cancer cell lines were cultured in alpha
minimal essential medium (α-MEM) containing 10% fetal
bovine serum, 100 U/mL penicillin and 100 μg/mL strep-
tomycin. Human cervical carcinoma (HeLa) cells were
cultured and maintained in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% FBS, 100 U/
ml penicillin and 100 μg/mL streptomycin. UMR-106 rat
osteosarcoma cell line was cultured in DMEM supple-
mented with 10% fetal bovine serum, 1 mM sodium pyru-
vate, 100 U/mL penicillin and 100 μg/mL streptomycin.
Stable CBFβ knockdown MDA-MB-231 cell line
These cell lines were established by a method described
previously [28], using SureSilencing shRNA plasmids for
human CBFβ (SABiosciences). Transfected cells were
selected by the addition of 1 μg/mL puromycin into the
media. Surviving cells were then assessed for the relative
e x p r e s s i o n  o f  C B F β  c o m p a r e d  w i t h  t h e  n o n s p e c i f i c -
transfected control cell line by western blot, and the
clones with the greatest degree of knockdown were
selected for subsequent experiments.Mendoza-Villanueva et al. Molecular Cancer 2010, 9:171
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Nuclear and cytoplasmic extracts
Nuclear extracts from mammalian cells were routinely
prepared as previously described [29]. The nuclear and
cytoplasmic extracts were subjected to a SDS-PAGE fol-
lowed by western blot.
Immunoprecipitation and Western Blot
Whole cell extract preparations were incubated with 3 μg
of Runx2 antibody (MBL) followed by incubation with
Protein G agarose beads. Normal mouse IgG was used as
a control. Washed beads were boiled with 50 μl of loading
buffer ([0.625 M] Tris-Cl pH 6.8, 50% glycerol, 10% SDS,
10% β-mercaptoethanol, 0.05% bromophenol blue). For
western blot, the samples were denatured with loading
buffer and heated at 100°C prior to loading onto 12% SDS
polyacrylamide gel. Proteins were detected with a mouse
monoclonal anti-Runx2 (MBL), whole serum anti-Runx2
or rabbit polyclonal anti-CBFβ antibodies (Abcam). Goat
anti-mouse IgG or anti-rabbit IgG conjugated with horse-
radish peroxidase (Pierce), were used as secondary anti-
bodies. Immune complexes were detected by Supersignal
W e s t  D u r a  E x t e n d e d  D u r a t i o n  S u b s t r a t e  ( P i e r c e )  a s
described previously [30].
Luciferase constructs and plasmids
Genomic DNA from MDA-MB-231 cells was isolated fol-
lowing standard protocols. The human OPN promoter
from -170/20 was cloned using primers 5'-GGCG-
GGCTCGAGGTGTGTGTGCGTTTTTGTTTTTT-3'
and 5'-CCCGCCAAGCTTTGCCTCCTCCTGCTGCT-
GCT-3'. The 5' and 3' primers contain a XhoI and a Hin-
dIII site respectively. The amplified OPN promoter
fragment was cloned into the promoter-basic luciferase
reporter plasmid pGL3B (Promega). The mutant OPN
promoter reporter was generated by site directed muta-
genesis (Stratagene), changing the Runx2-binding site,
ACCACA, to ACAGCA. The pGL3MMP-13 promoter
reporter plasmid encoding the wild-type promoter
sequence has been described previously [31].
pGL3MMP-13mut was generated by mutating the distal
Runx2 site in the pGL3MMP-13 promoter already har-
bouring a mutation in the proximal Runx-binding site
[31]. The subsequent plasmid has both proximal and dis-
tal Runx2-binding sites mutated. The plasmid Flag-
CBFβ-HA (CBFβ*) was generated by introducing the
CBFβ mouse cDNA into pcDNA3 flanked by Flag and
HA tags at the N-terminus and C-terminus, respectively.
Transient transfections and siRNAs
Cells were cultivated in 6-well plates at a concentration of
1.5 × 105 cells/well at 37°C and 5% CO2 atmosphere, 24
hours before transfection. Transfections were performed
using lipofectamine 2000 (Invitrogen). For the luciferase
assays the cells were transfected with 350 ng of the
luciferase plasmids and 50 ng of Renilla luciferase plas-
mid and cotransfected with 400 ng of plasmid CBFβ* or
pCDNA3, DNA was maintained in equal amounts. After
48 h, cells were harvested and lysates were measured for
luciferase activity and normalized for transfection effi-
ciency to Renilla luciferase activity (dual-luciferase
reporter assay system, Promega). The relative reporter
activity was obtained by comparison to mutant promoter
activity. All readings were performed in triplicate and in
three separate experiments. Data are presented as mean
± standard deviation (S.D.). MDA-MB-231 cells trans-
fected with siRNA against CBFβ (siCBFβ), Runx2
(siRunx2), or a nonspecific siRNA (siNS) (Santa Cruz
Biotechnology), were performed with oligofectamine
(Invitrogen). 24 hrs after a second transfection the cells
were used for mRNA extraction or invasion assays.
Real-time RT-PCR
Total mRNA was isolated from cell pellets using an
RNeasy mini kit (QIAGEN); genomic DNA was removed
using the RNase-free DNase set (QIAGEN). mRNA
expression of the selected genes was determined by real-
time PCR using one-step QuantiTect SYBR Green RT-
PCR kit (QIAGEN) according to the manufacturer's pro-
tocol. Nucleotide sequences of specific primers for the
different genes were: Acidic ribosomal phosphoprotein
P0 (RPLO), forward 5'-GGCGACCTGGAAGTCCAA-3'
and reverse 5'-CCATCAGCACCACAGCCTT-3'; Runt-
related transcription factor 2 (Runx2), forward 5'-AGCC
CTCGGAGAGGTACCA-3' and reverse 5'-CGGAGCT-
CAGCAGAATAATTTTC-3'; Core binding factor beta
(CBFβ), forward 5'-CTTAGAAAGAGAAGCAGGCA
AGG-3' and reverse 5'-AACTCCAGACAGCCCAT-
ACCA-3'; Matrix metalloproteinase 13 (MMP-13), for-
ward 5'-AAATTATGGAGGAGATGCCCATT-3' and
reverse 5'-TCCTTGGAGTGGTCAAGACCTAA-3';
Osteopontin (OPN), forward 5'-TTGCAGCCTTCT-
CAGCCA-3' and reverse 5'-CAAAAGCAAATCACTG-
CAATTCT-3'; Matrix metalloproteinase 9 (MMP-9),
forward 5'-ACCACAACATCACCTATTGGATC-3' and
reverse 5'-ACCAAACT GGATGACGATGTCT-3';
Osteocalcin (OC), forward 5'-GTGCAGAGTCCAG-
CAAAGGTG -3' and reverse 5'-CAGCCAACTCGTCA-
CAGTCC-3'; Galectin-3, forward 5'-GGGCCACTGA
TTGTGCCT-3' and reverse 5'-TGTTGTTCTCATT-
GAAGCGTGG-3'. Thermocycler conditions included an
initial reverse transcription at 50°C for 30 minutes, then
95°C for 15 minutes; this was followed by a PCR program:
94°C for 30 seconds, 60°C for 45 seconds and 72°C for 45
seconds for 40 cycles. Data were collected and analysed
on a Chromo4 Real-Time PCR sequence detection system
(Biorad). Data are presented as mean ± standard devia-
tion (S.D.).Mendoza-Villanueva et al. Molecular Cancer 2010, 9:171
http://www.molecular-cancer.com/content/9/1/171
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Invasion Assays
Cells were analyzed for invasion through Matrigel 24 well
plates according to the manufacturer's protocol (BD Bio-
sciences). Briefly, cells were placed in Matrigel inserts at
1.8 × 104  cells/ml in serum-free medium and were
allowed to migrate for 22 hrs at 37°C. Non-migrating cells
were removed from the top of the filter by scrubbing with
a cotton swab. Cells that migrated were fixed and stained
with DAPI (ProLong Gold, Invitrogen). Cells that
migrated through the Matrigel were counted manually.
Data are presented as mean ± standard deviation (S.D.).
ChIP assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed according to the published method with modifi-
cations [32]. Briefly, MDA-MB-231 cells were cross-
linked with 1% formaldehyde-phosphate-buffered saline
for 10 minutes at room temperature and quenched by the
addition of glycine to a final concentration of 250 mM.
The cells were washed twice with cold phosphate-buff-
ered saline and harvested. The cell pellet was resus-
pended in lysis buffer (50 mM Tris-Cl, pH 8.0, 10 mM
EDTA, 1% sodium dodecyl sulfate). Samples were then
sonicated for 15 minutes at high power with a Diagenode
sonicator. After sonication, the samples were centrifuged
in a benchtop microcentrifuge at 4°C, and the superna-
tants were diluted with ChIP dilution buffer (0.01%
sodium dodecyl sulfate, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris-Cl, pH 8.0, 167 mM NaCl). For
immunoprecipitation, the samples were pre-cleared using
10 μl Dynabeads protein A (Invitrogen). Four micro-
grams of each antibody (CBFβ or Runx2 or control IgG)
was added to the sample, and the samples were incubated
overnight at 4°C, followed by the addition of 10 μl Dyna-
beads protein A and incubation for 1 h at room tempera-
ture. The remainder of the procedure was followed
according to the method described previously [32]. The
DNA was isolated with Qiagen DNA purification kit. Real
time PCR was performed with Osteopontin promoter
primers (forward: 5'-TGAATGCCCATCCCGTAAA-3';
reverse: 5'-ATGCCCATCCCGTAAATGA-3'); 18S gene
primers (forward: 5'-GTAACCCGTTGAACCCCATT-3'
reverse: 5'-CCATCCAATCGGTAGTAGCG-3') and
Galectin-3 as previously reported [33]. The relative
enrichment of target DNA was determined by calculating
the ratio of DNA from specific antibody to that from con-
trol IgG, and normalized by 18S non-specific genomic
DNA within the same sample. Data are presented as
mean ± standard deviation (S.D.).
Statistical Analyses
One-way analysis of variance was used to determine sta-
tistical differences between groups using SPSS software
(Chicago, IL). A p value < 0.05 was considered statistically
significant. Multiple comparisons between individual
groups were assessed by the method of Tukey. Compari-
sons of multiple groups to a single control were done
according to the method of Dunnett. For comparison of
mRNA, statistical evaluation of significant differences
was performed using the Student's t-test. Asterisk (*)
indicates P < 0.05 when compared to control and were
considered statistically significant.
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